Management of peritoneal carcinomatosis continues to evolve from previous therapy limited to palliative interventions to current advanced therapy with curative intent. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) likewise has progressed from experimental therapy to a well-accepted standard oncologic procedure. CRS-HIPEC continues to be more frequently utilized worldwide, particularly for the management of carcinomatosis secondary to colorectal and appendiceal cancers. The treatment algorithm for many advanced gastrointestinal cancers includes neoadjuvant chemotherapy (NAT). The Chicago Consensus Working Group recommends NAT prior to CRS-HIPEC for appendiceal and colorectal adenocarcinomas.
1,2 The effect of NAT on subsequent HIPEC is greatly unknown and has not been previously studied. …